117 related articles for article (PubMed ID: 22172900)
1. Prognostic factors for survival and resection in patients with initial nonresectable locally advanced pancreatic cancer treated with chemoradiotherapy.
Bjerregaard JK; Mortensen MB; Jensen HA; Nielsen M; Pfeiffer P
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):909-15. PubMed ID: 22172900
[TBL] [Abstract][Full Text] [Related]
2. Salvage chemoradiotherapy after primary chemotherapy for locally advanced pancreatic cancer: a single-institution retrospective analysis.
Mayahara H; Ito Y; Morizane C; Ueno H; Okusaka T; Kondo S; Murakami N; Morota M; Sumi M; Itami J
BMC Cancer; 2012 Dec; 12():609. PubMed ID: 23256481
[TBL] [Abstract][Full Text] [Related]
3. Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer.
Chiorean EG; Schneider BP; Akisik FM; Perkins SM; Anderson S; Johnson CS; DeWitt J; Helft P; Clark R; Johnston EL; Spittler AJ; Deluca J; Bu G; Shahda S; Loehrer PJ; Sandrasegaran K; Cardenes HR
Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):284-91. PubMed ID: 24726286
[TBL] [Abstract][Full Text] [Related]
4. Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic Cancer.
Wild AT; Herman JM; Dholakia AS; Moningi S; Lu Y; Rosati LM; Hacker-Prietz A; Assadi RK; Saeed AM; Pawlik TM; Jaffee EM; Laheru DA; Tran PT; Weiss MJ; Wolfgang CL; Ford E; Grossman SA; Ye X; Ellsworth SG
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):571-9. PubMed ID: 26867885
[TBL] [Abstract][Full Text] [Related]
5. Analysis of dosimetric parameters associated with acute gastrointestinal toxicity and upper gastrointestinal bleeding in locally advanced pancreatic cancer patients treated with gemcitabine-based concurrent chemoradiotherapy.
Nakamura A; Shibuya K; Matsuo Y; Nakamura M; Shiinoki T; Mizowaki T; Hiraoka M
Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):369-75. PubMed ID: 22381898
[TBL] [Abstract][Full Text] [Related]
6. Baseline metabolic tumor volume and total lesion glycolysis are associated with survival outcomes in patients with locally advanced pancreatic cancer receiving stereotactic body radiation therapy.
Dholakia AS; Chaudhry M; Leal JP; Chang DT; Raman SP; Hacker-Prietz A; Su Z; Pai J; Oteiza KE; Griffith ME; Wahl RL; Tryggestad E; Pawlik T; Laheru DA; Wolfgang CL; Koong AC; Herman JM
Int J Radiat Oncol Biol Phys; 2014 Jul; 89(3):539-46. PubMed ID: 24751410
[TBL] [Abstract][Full Text] [Related]
7. miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial.
Khan K; Cunningham D; Peckitt C; Barton S; Tait D; Hawkins M; Watkins D; Starling N; Rao S; Begum R; Thomas J; Oates J; Guzzardo V; Fassan M; Braconi C; Chau I
Oncotarget; 2016 Mar; 7(11):12672-81. PubMed ID: 26862857
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine and S-1 Induction Chemotherapy Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancers.
Maemura K; Mataki Y; Kurahara H; Kawasaki Y; Iino S; Sakoda M; Uchikado Y; Arigami T; Uenosono Y; Mori S; Ueno S; Shinchi H; Natsugoe S
Anticancer Res; 2017 Jan; 37(1):233-237. PubMed ID: 28011497
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant Gemcitabine and Gemcitabine-based Chemoradiotherapy Versus Gemcitabine Alone After Pancreatic Cancer Resection: The Indiana University Experience.
Khawaja MR; Kleyman S; Yu Z; Howard T; Burns M; Nakeeb A; Loehrer PJ; Cardenes HR; Chiorean EG
Am J Clin Oncol; 2017 Feb; 40(1):42-46. PubMed ID: 25121637
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine-based concurrent chemoradiotherapy versus chemotherapy alone in patients with locally advanced pancreatic cancer.
Wang BH; Cao WM; Yu J; Wang XL
Asian Pac J Cancer Prev; 2012; 13(5):2129-32. PubMed ID: 22901181
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of induction gemcitabine and S-1 followed by chemoradiotherapy and systemic chemotherapy using S-1 for locally advanced pancreatic cancer.
Sudo K; Hara R; Nakamura K; Kita E; Tsujimoto A; Yamaguchi T
Cancer Chemother Pharmacol; 2017 Jul; 80(1):195-202. PubMed ID: 28597040
[TBL] [Abstract][Full Text] [Related]
12. Histopathological effects of preoperative chemoradiotherapy for pancreatic cancer: an analysis for the impact of radiation and gemcitabine doses.
Hirata T; Teshima T; Nishiyama K; Ogawa K; Otani K; Kawaguchi Y; Konishi K; Tomita Y; Takahashi H; Ohigashi H; Ishikawa O
Radiother Oncol; 2015 Jan; 114(1):122-7. PubMed ID: 25614389
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer.
Habermehl D; Kessel K; Welzel T; Hof H; Abdollahi A; Bergmann F; Rieken S; Weitz J; Werner J; Schirmacher P; Büchler MW; Debus J; Combs SE
Radiat Oncol; 2012 Mar; 7():28. PubMed ID: 22385572
[TBL] [Abstract][Full Text] [Related]
14. Predictors of Hematologic Toxicity and Chemotherapy Dose Intensity in Patients Undergoing Chemoradiation for Pancreatic Cancer.
Shaikh T; Wang LS; Egleston B; Burki M; Hoffman JP; Cohen SJ; Meyer JE
Am J Clin Oncol; 2018 Jan; 41(1):59-64. PubMed ID: 26325492
[TBL] [Abstract][Full Text] [Related]
15. Concurrent chemoradiotherapy with or without induction chemotherapy versus chemotherapy alone in patients with locally advanced pancreatic cancer.
Huang WK; Kuo YC; Tsang NM; Hsu HC; Shen WC; Chou WC; Yang TS; Chen JS
Anticancer Res; 2014 Nov; 34(11):6755-61. PubMed ID: 25368287
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer.
Mahadevan A; Jain S; Goldstein M; Miksad R; Pleskow D; Sawhney M; Brennan D; Callery M; Vollmer C
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):735-42. PubMed ID: 20171803
[TBL] [Abstract][Full Text] [Related]
17. High-dose helical tomotherapy with concurrent full-dose chemotherapy for locally advanced pancreatic cancer.
Chang JS; Wang ML; Koom WS; Yoon HI; Chung Y; Song SY; Seong J
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1448-54. PubMed ID: 22285669
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Significance of a Minute Amount of Ascites During Chemoradiotherapy for Locally Advanced Pancreatic Cancer.
Shinoto M; Nakamura K; Shioyama Y; Sasaki T; Nishie A; Asayama Y; Ohga S; Yoshitake T; Terashima K; Asai K; Matsumoto K; Honda H
Anticancer Res; 2016 Apr; 36(4):1879-84. PubMed ID: 27069174
[TBL] [Abstract][Full Text] [Related]
19. Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradiotherapy for pancreatic cancer.
Willenbrock F; Cox CM; Parkes EE; Wilhelm-Benartzi CS; Abraham AG; Owens R; Sabbagh A; Jones CM; Hughes DLI; Maughan T; Hurt CN; O'Neill EE; Mukherjee S
Br J Cancer; 2021 Feb; 124(3):581-586. PubMed ID: 33100327
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant radiotherapy and chemoradiation with gemcitabine after R1 resection in patients with pancreatic adenocarcinoma.
Habermehl D; Brecht IC; Bergmann F; Rieken S; Werner J; Büchler MW; Springfeld C; Jäger D; Debus J; Combs SE
World J Surg Oncol; 2015 Apr; 13():149. PubMed ID: 25889749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]